研究关注：Pfizer and Arvinas give disappointing breast cancer drug to Rigel

## 事件概览

Pfizer has turned $1 billion into $35 million. The New York-based pharma company and its partner Arvinas are selling rights to their recentl...

## 核心信息

Pfizer has turned $1 billion into $35 million. The New York-based pharma company and its partner Arvinas are selling rights to their recently approved breast cancer drug to Rigel Pharmaceuticals. They decided last year that ...

## 为什么值得关注

这条内容与 cancer 相关，可能影响科研选题、技术趋势判断或产业观察。BioDir 已根据来源、摘要长度、主题词和潜在影响给出 32 分的候选评分。

## 发布提示

发布前应核对原文链接、研究对象、样本规模、方法限制和结论边界。若来源为 bioRxiv 或 medRxiv，应明确标注其为预印本，尚未经过同行评议。